Documentos relacionados

1. Tumor necrosis factor-α inhibitor-induced follicular psoriasiform eruption.
2. Infliximab-induced psoriasis in children with inflammatory bowel disease.
3. Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report.
4. Vedolizumab-associated psoriasis: until where does gut selectivity go?
5. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.
6. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
7. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
8. Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.
9. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
10. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.